Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment
- Conditions
- Gastrointestinal Complication
- Registration Number
- NCT04880473
- Lead Sponsor
- Entac Medical Inc.
- Brief Summary
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first 24 hours after surgery, a failure to successfully orally re-feed a subject is defined as presentation with emesis, requiring a reversal of diet, or the placement of a nasogastric tube on first postoperative day or later.
The device is considered non-significant risk (NSR). The device does not inform medical decisions in this study. Researchers will be blinded to results of the device during this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 400
-
Age ≥ 18 and ≤ 90 years
-
Patient undergoing elective intestinal resection surgery including open, laparoscopic, robotic, or hand-assist technique for:
- Segmental ileocolic resection with or without diversion
- Segmental colon resection with or without diversion
- Segmental coloproctectomy with or without diversion
- Low anterior resection with or without diversion
- Abdominoperineal resection
- Total abdominal colectomy with or without diversion
- Proctocolectomy with or without end ileostomy or diversion
- Closure of end colostomy (Hartmann's reversal)
-
Allergies to any of the device components (i.e., adhesive)
-
Inability to have prototype device applied to their abdominal wall due to disease conditions or surgical alterations(e.g., fistulas, stomas, drains, etc.)
-
Patients undergoing:
- Small bowel resection without colonic resection
- Transanal proctectomy without transabdominal approach
- Perineal proctosigmoidectomy
- Closure of loop colostomy or ileostomy
-
Patients with preoperative evidence of an anastomotic leak, deep wound infection, organ space infection, or urinary tract infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Performance of the PrevisEA device 1-14 days The performance (accuracy) of the device in predicting development of GII will be assessed through evaluation of the primary outcome measures of sensitivity and specificity for the device.
- Secondary Outcome Measures
Name Time Method Positive predictive value (PPV) 1-14 days Measures will be analyzed by using available data only
Overall percent agreement (OPA) 1-14 days Measures will be analyzed by using available data only
Negative predictive value (NPV) 1-14 days Measures will be analyzed by using available data only
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (8)
Adventist Health System/Sunbelt, Inc. d/b/a AdventHealth Orlando
🇺🇸Orlando, Florida, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Spectrum Health Blodgett Hospital
🇺🇸Grand Rapids, Michigan, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
The University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
The Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Adventist Health System/Sunbelt, Inc. d/b/a AdventHealth Orlando🇺🇸Orlando, Florida, United StatesDevonnae SterlingContactdevonnae.sterling@AdventHealth.com